NCT03436394View on ClinicalTrials.gov

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

February 22, 2019

Study Completion Date

February 22, 2019

Conditions
Renal Impairment
Interventions
DRUG

Evobrutinib

Subjects will be administered a single oral dose of evobrutinib under fasting conditions.

Trial Locations (1)

64293

Please Contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03436394 - Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) | Biotech Hunter | Biotech Hunter